

Global Antibody Drug Conjugate CDMO Market Growth (Status and Outlook) 2025-2031

<https://marketpublishers.com/r/G1D1C64FF12DEN.html>

Date: August 2025

Pages: 132

Price: US\$ 3,660.00 (Single User License)

ID: G1D1C64FF12DEN

Abstracts

According to this study, the global Antibody Drug Conjugate CDMO market size will reach US\$ 7354 million by 2031.

Antibody-Drug Conjugate (ADC) is a type of targeted cancer therapy that utilizes monoclonal antibodies to deliver cytotoxic drugs directly to cancer cells, minimizing damage to healthy cells. ADCs have shown promising results in treating various types of cancers. A Contract Development and Manufacturing Organization (CDMO) specializes in providing services related to the development, manufacturing, and testing of pharmaceuticals, including biologics like ADCs.

Antibody Drug Conjugates (ADCs) represent one of the fastest-growing and most sophisticated segments in targeted cancer therapy. By combining the precise targeting ability of monoclonal antibodies with the potent cell-killing effect of cytotoxic drugs, ADCs offer a powerful treatment strategy that minimizes harm to healthy tissues.

However, ADCs are among the most complex biologic-drug hybrids to manufacture — they require expertise in biologics production, high-potency active pharmaceutical ingredient (HPAPI) synthesis, advanced conjugation technology, and high-containment fill-finish capabilities.

This is where Contract Development and Manufacturing Organizations (CDMOs) come in. They provide specialized technical infrastructure and know-how for biopharma companies that want to develop and commercialize ADCs without building expensive in-house capacity.

The ADC CDMO market has grown significantly in recent years, fueled by an expanding

pipeline of ADCs in clinical trials and rising numbers of commercial approvals. Leading CDMOs now offer end-to-end solutions covering monoclonal antibody production, payload synthesis, conjugation, and sterile, high-containment packaging.

Growing Number of Approved ADCs and Robust Clinical Pipeline

More than a dozen ADCs have received regulatory approval worldwide, with blockbusters like Enhertu®, Padcev®, and Polivy® demonstrating strong commercial success. At the same time, hundreds of new ADCs are in preclinical and clinical development targeting a wide range of cancers and even some non-oncology indications. This expanding pipeline fuels sustained demand for expert CDMO services from early development through to commercial scale-up.

Rising Demand for End-to-End Solutions

Pharma companies increasingly prefer one-stop CDMO partners that can handle the entire ADC value chain — from cell line development to final fill-finish — under a single quality system and contract. This integrated model simplifies supply chains, shortens development timelines, and reduces risk, giving CDMOs with full-spectrum ADC capabilities a competitive edge.

Increased Investment in High-Potency Manufacturing Capacity

As the ADC market expands, leading CDMOs are investing heavily to expand or build new high-containment suites and HPAPI production lines. This growth is critical because HPAPI synthesis and handling require specialized equipment, isolated work areas, and rigorous operator safety systems.

Companies like Lonza, WuXi XDC, Piramal Pharma Solutions, and Sterling Pharma Solutions have made significant capital investments to meet the increasing global demand.

LPI (LP Information)' newest research report, the “Antibody Drug Conjugate CDMO Industry Forecast” looks at past sales and reviews total world Antibody Drug Conjugate CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Antibody Drug Conjugate CDMO sales for 2025 through 2031. With Antibody Drug Conjugate CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Antibody Drug Conjugate CDMO industry.

This Insight Report provides a comprehensive analysis of the global Antibody Drug Conjugate CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antibody Drug Conjugate CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Antibody Drug Conjugate CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody Drug Conjugate CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody Drug Conjugate CDMO.

This report presents a comprehensive overview, market shares, and growth opportunities of Antibody Drug Conjugate CDMO market by product type, application, key players and key regions and countries.

Segmentation by Type:

Cleavable Linker ADCs

Non-Cleavable Linker ADCs

Segmentation by Application:

Small and Medium-sized Pharmaceutical Companies

Large Pharmaceutical Companies

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Lonza Group

Porton Pharma Solutions

WuXi XDC

BOC Sciences

Asymchem

Catalent Biologics

3PBIOVIAN

Genscript

AGC Biologics

MabPlex

ChemExpress

Abzena

Ajinomoto Bio-Pharma Services

BSP Pharmaceuticals

AbbVie Contract Manufacturing

TOT Biopharm

Huadong Medicine

Innovent Biologics

Zhenhao Biology

Porton Pharma Solutions

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Antibody Drug Conjugate CDMO Market Size (2020-2031)
 - 2.1.2 Antibody Drug Conjugate CDMO Market Size CAGR by Region (2020 VS 2024 VS 2031)
 - 2.1.3 World Current & Future Analysis for Antibody Drug Conjugate CDMO by Country/Region (2020, 2024 & 2031)
- 2.2 Antibody Drug Conjugate CDMO Segment by Type
 - 2.2.1 Cleavable Linker ADCs
 - 2.2.2 Non-Cleavable Linker ADCs
- 2.3 Antibody Drug Conjugate CDMO Market Size by Type
 - 2.3.1 Antibody Drug Conjugate CDMO Market Size CAGR by Type (2020 VS 2024 VS 2031)
 - 2.3.2 Global Antibody Drug Conjugate CDMO Market Size Market Share by Type (2020-2025)
- 2.4 Antibody Drug Conjugate CDMO Segment by Application
 - 2.4.1 Small and Medium-sized Pharmaceutical Companies
 - 2.4.2 Large Pharmaceutical Companies
- 2.5 Antibody Drug Conjugate CDMO Market Size by Application
 - 2.5.1 Antibody Drug Conjugate CDMO Market Size CAGR by Application (2020 VS 2024 VS 2031)
 - 2.5.2 Global Antibody Drug Conjugate CDMO Market Size Market Share by Application (2020-2025)

3 ANTIBODY DRUG CONJUGATE CDMO MARKET SIZE BY PLAYER

- 3.1 Antibody Drug Conjugate CDMO Market Size Market Share by Player
 - 3.1.1 Global Antibody Drug Conjugate CDMO Revenue by Player (2020-2025)
 - 3.1.2 Global Antibody Drug Conjugate CDMO Revenue Market Share by Player (2020-2025)
- 3.2 Global Antibody Drug Conjugate CDMO Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
 - 3.3.1 Competition Landscape Analysis
 - 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion

4 ANTIBODY DRUG CONJUGATE CDMO BY REGION

- 4.1 Antibody Drug Conjugate CDMO Market Size by Region (2020-2025)
- 4.2 Global Antibody Drug Conjugate CDMO Annual Revenue by Country/Region (2020-2025)
- 4.3 Americas Antibody Drug Conjugate CDMO Market Size Growth (2020-2025)
- 4.4 APAC Antibody Drug Conjugate CDMO Market Size Growth (2020-2025)
- 4.5 Europe Antibody Drug Conjugate CDMO Market Size Growth (2020-2025)
- 4.6 Middle East & Africa Antibody Drug Conjugate CDMO Market Size Growth (2020-2025)

5 AMERICAS

- 5.1 Americas Antibody Drug Conjugate CDMO Market Size by Country (2020-2025)
- 5.2 Americas Antibody Drug Conjugate CDMO Market Size by Type (2020-2025)
- 5.3 Americas Antibody Drug Conjugate CDMO Market Size by Application (2020-2025)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Antibody Drug Conjugate CDMO Market Size by Region (2020-2025)
- 6.2 APAC Antibody Drug Conjugate CDMO Market Size by Type (2020-2025)
- 6.3 APAC Antibody Drug Conjugate CDMO Market Size by Application (2020-2025)

- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia

7 EUROPE

- 7.1 Europe Antibody Drug Conjugate CDMO Market Size by Country (2020-2025)
- 7.2 Europe Antibody Drug Conjugate CDMO Market Size by Type (2020-2025)
- 7.3 Europe Antibody Drug Conjugate CDMO Market Size by Application (2020-2025)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Antibody Drug Conjugate CDMO by Region (2020-2025)
- 8.2 Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Type (2020-2025)
- 8.3 Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Application (2020-2025)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL ANTIBODY DRUG CONJUGATE CDMO MARKET FORECAST

- 10.1 Global Antibody Drug Conjugate CDMO Forecast by Region (2026-2031)
 - 10.1.1 Global Antibody Drug Conjugate CDMO Forecast by Region (2026-2031)
 - 10.1.2 Americas Antibody Drug Conjugate CDMO Forecast
 - 10.1.3 APAC Antibody Drug Conjugate CDMO Forecast
 - 10.1.4 Europe Antibody Drug Conjugate CDMO Forecast
 - 10.1.5 Middle East & Africa Antibody Drug Conjugate CDMO Forecast
- 10.2 Americas Antibody Drug Conjugate CDMO Forecast by Country (2026-2031)
 - 10.2.1 United States Market Antibody Drug Conjugate CDMO Forecast
 - 10.2.2 Canada Market Antibody Drug Conjugate CDMO Forecast
 - 10.2.3 Mexico Market Antibody Drug Conjugate CDMO Forecast
 - 10.2.4 Brazil Market Antibody Drug Conjugate CDMO Forecast
- 10.3 APAC Antibody Drug Conjugate CDMO Forecast by Region (2026-2031)
 - 10.3.1 China Antibody Drug Conjugate CDMO Market Forecast
 - 10.3.2 Japan Market Antibody Drug Conjugate CDMO Forecast
 - 10.3.3 Korea Market Antibody Drug Conjugate CDMO Forecast
 - 10.3.4 Southeast Asia Market Antibody Drug Conjugate CDMO Forecast
 - 10.3.5 India Market Antibody Drug Conjugate CDMO Forecast
 - 10.3.6 Australia Market Antibody Drug Conjugate CDMO Forecast
- 10.4 Europe Antibody Drug Conjugate CDMO Forecast by Country (2026-2031)
 - 10.4.1 Germany Market Antibody Drug Conjugate CDMO Forecast
 - 10.4.2 France Market Antibody Drug Conjugate CDMO Forecast
 - 10.4.3 UK Market Antibody Drug Conjugate CDMO Forecast
 - 10.4.4 Italy Market Antibody Drug Conjugate CDMO Forecast
 - 10.4.5 Russia Market Antibody Drug Conjugate CDMO Forecast
- 10.5 Middle East & Africa Antibody Drug Conjugate CDMO Forecast by Region (2026-2031)
 - 10.5.1 Egypt Market Antibody Drug Conjugate CDMO Forecast
 - 10.5.2 South Africa Market Antibody Drug Conjugate CDMO Forecast
 - 10.5.3 Israel Market Antibody Drug Conjugate CDMO Forecast
 - 10.5.4 Turkey Market Antibody Drug Conjugate CDMO Forecast
- 10.6 Global Antibody Drug Conjugate CDMO Forecast by Type (2026-2031)
- 10.7 Global Antibody Drug Conjugate CDMO Forecast by Application (2026-2031)
 - 10.7.1 GCC Countries Market Antibody Drug Conjugate CDMO Forecast

11 KEY PLAYERS ANALYSIS

- 11.1 Lonza Group
 - 11.1.1 Lonza Group Company Information
 - 11.1.2 Lonza Group Antibody Drug Conjugate CDMO Product Offered

11.1.3 Lonza Group Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.1.4 Lonza Group Main Business Overview

11.1.5 Lonza Group Latest Developments

11.2 Porton Pharma Solutions

11.2.1 Porton Pharma Solutions Company Information

11.2.2 Porton Pharma Solutions Antibody Drug Conjugate CDMO Product Offered

11.2.3 Porton Pharma Solutions Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.2.4 Porton Pharma Solutions Main Business Overview

11.2.5 Porton Pharma Solutions Latest Developments

11.3 WuXi XDC

11.3.1 WuXi XDC Company Information

11.3.2 WuXi XDC Antibody Drug Conjugate CDMO Product Offered

11.3.3 WuXi XDC Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.3.4 WuXi XDC Main Business Overview

11.3.5 WuXi XDC Latest Developments

11.4 BOC Sciences

11.4.1 BOC Sciences Company Information

11.4.2 BOC Sciences Antibody Drug Conjugate CDMO Product Offered

11.4.3 BOC Sciences Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.4.4 BOC Sciences Main Business Overview

11.4.5 BOC Sciences Latest Developments

11.5 Asymchem

11.5.1 Asymchem Company Information

11.5.2 Asymchem Antibody Drug Conjugate CDMO Product Offered

11.5.3 Asymchem Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.5.4 Asymchem Main Business Overview

11.5.5 Asymchem Latest Developments

11.6 Catalent Biologics

11.6.1 Catalent Biologics Company Information

11.6.2 Catalent Biologics Antibody Drug Conjugate CDMO Product Offered

11.6.3 Catalent Biologics Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.6.4 Catalent Biologics Main Business Overview

11.6.5 Catalent Biologics Latest Developments

11.7 3PBIOVIAN

11.7.1 3PBIOVIAN Company Information

11.7.2 3PBIOVIAN Antibody Drug Conjugate CDMO Product Offered

11.7.3 3PBIOVIAN Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.7.4 3PBIOVIAN Main Business Overview

11.7.5 3PBIOVIAN Latest Developments

11.8 Genscript

11.8.1 Genscript Company Information

11.8.2 Genscript Antibody Drug Conjugate CDMO Product Offered

11.8.3 Genscript Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.8.4 Genscript Main Business Overview

11.8.5 Genscript Latest Developments

11.9 AGC Biologics

11.9.1 AGC Biologics Company Information

11.9.2 AGC Biologics Antibody Drug Conjugate CDMO Product Offered

11.9.3 AGC Biologics Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.9.4 AGC Biologics Main Business Overview

11.9.5 AGC Biologics Latest Developments

11.10 MabPlex

11.10.1 MabPlex Company Information

11.10.2 MabPlex Antibody Drug Conjugate CDMO Product Offered

11.10.3 MabPlex Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.10.4 MabPlex Main Business Overview

11.10.5 MabPlex Latest Developments

11.11 ChemExpress

11.11.1 ChemExpress Company Information

11.11.2 ChemExpress Antibody Drug Conjugate CDMO Product Offered

11.11.3 ChemExpress Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.11.4 ChemExpress Main Business Overview

11.11.5 ChemExpress Latest Developments

11.12 Abzena

11.12.1 Abzena Company Information

11.12.2 Abzena Antibody Drug Conjugate CDMO Product Offered

11.12.3 Abzena Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market

Share (2020-2025)

11.12.4 Abzena Main Business Overview

11.12.5 Abzena Latest Developments

11.13 Ajinomoto Bio-Pharma Services

11.13.1 Ajinomoto Bio-Pharma Services Company Information

11.13.2 Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Product Offered

11.13.3 Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.13.4 Ajinomoto Bio-Pharma Services Main Business Overview

11.13.5 Ajinomoto Bio-Pharma Services Latest Developments

11.14 BSP Pharmaceuticals

11.14.1 BSP Pharmaceuticals Company Information

11.14.2 BSP Pharmaceuticals Antibody Drug Conjugate CDMO Product Offered

11.14.3 BSP Pharmaceuticals Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.14.4 BSP Pharmaceuticals Main Business Overview

11.14.5 BSP Pharmaceuticals Latest Developments

11.15 AbbVie Contract Manufacturing

11.15.1 AbbVie Contract Manufacturing Company Information

11.15.2 AbbVie Contract Manufacturing Antibody Drug Conjugate CDMO Product Offered

11.15.3 AbbVie Contract Manufacturing Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.15.4 AbbVie Contract Manufacturing Main Business Overview

11.15.5 AbbVie Contract Manufacturing Latest Developments

11.16 TOT Biopharm

11.16.1 TOT Biopharm Company Information

11.16.2 TOT Biopharm Antibody Drug Conjugate CDMO Product Offered

11.16.3 TOT Biopharm Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.16.4 TOT Biopharm Main Business Overview

11.16.5 TOT Biopharm Latest Developments

11.17 Huadong Medicine

11.17.1 Huadong Medicine Company Information

11.17.2 Huadong Medicine Antibody Drug Conjugate CDMO Product Offered

11.17.3 Huadong Medicine Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.17.4 Huadong Medicine Main Business Overview

11.17.5 Huadong Medicine Latest Developments

11.18 Innovent Biologics

11.18.1 Innovent Biologics Company Information

11.18.2 Innovent Biologics Antibody Drug Conjugate CDMO Product Offered

11.18.3 Innovent Biologics Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.18.4 Innovent Biologics Main Business Overview

11.18.5 Innovent Biologics Latest Developments

11.19 Zhenhao Biology

11.19.1 Zhenhao Biology Company Information

11.19.2 Zhenhao Biology Antibody Drug Conjugate CDMO Product Offered

11.19.3 Zhenhao Biology Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.19.4 Zhenhao Biology Main Business Overview

11.19.5 Zhenhao Biology Latest Developments

11.20 Porton Pharma Solutions

11.20.1 Porton Pharma Solutions Company Information

11.20.2 Porton Pharma Solutions Antibody Drug Conjugate CDMO Product Offered

11.20.3 Porton Pharma Solutions Antibody Drug Conjugate CDMO Revenue, Gross Margin and Market Share (2020-2025)

11.20.4 Porton Pharma Solutions Main Business Overview

11.20.5 Porton Pharma Solutions Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Antibody Drug Conjugate CDMO Market Size CAGR by Region (2020 VS 2024 VS 2031) & (\$ millions)

Table 2. Antibody Drug Conjugate CDMO Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & (\$ millions)

Table 3. Major Players of Cleavable Linker ADCs

Table 4. Major Players of Non-Cleavable Linker ADCs

Table 5. Antibody Drug Conjugate CDMO Market Size CAGR by Type (2020 VS 2024 VS 2031) & (\$ millions)

Table 6. Global Antibody Drug Conjugate CDMO Market Size by Type (2020-2025) & (\$ millions)

Table 7. Global Antibody Drug Conjugate CDMO Market Size Market Share by Type (2020-2025)

Table 8. Antibody Drug Conjugate CDMO Market Size CAGR by Application (2020 VS 2024 VS 2031) & (\$ millions)

Table 9. Global Antibody Drug Conjugate CDMO Market Size by Application (2020-2025) & (\$ millions)

Table 10. Global Antibody Drug Conjugate CDMO Market Size Market Share by Application (2020-2025)

Table 11. Global Antibody Drug Conjugate CDMO Revenue by Player (2020-2025) & (\$ millions)

Table 12. Global Antibody Drug Conjugate CDMO Revenue Market Share by Player (2020-2025)

Table 13. Antibody Drug Conjugate CDMO Key Players Head office and Products Offered

Table 14. Antibody Drug Conjugate CDMO Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)

Table 15. New Products and Potential Entrants

Table 16. Mergers & Acquisitions, Expansion

Table 17. Global Antibody Drug Conjugate CDMO Market Size by Region (2020-2025) & (\$ millions)

Table 18. Global Antibody Drug Conjugate CDMO Market Size Market Share by Region (2020-2025)

Table 19. Global Antibody Drug Conjugate CDMO Revenue by Country/Region (2020-2025) & (\$ millions)

Table 20. Global Antibody Drug Conjugate CDMO Revenue Market Share by

Country/Region (2020-2025)

Table 21. Americas Antibody Drug Conjugate CDMO Market Size by Country (2020-2025) & (\$ millions)

Table 22. Americas Antibody Drug Conjugate CDMO Market Size Market Share by Country (2020-2025)

Table 23. Americas Antibody Drug Conjugate CDMO Market Size by Type (2020-2025) & (\$ millions)

Table 24. Americas Antibody Drug Conjugate CDMO Market Size Market Share by Type (2020-2025)

Table 25. Americas Antibody Drug Conjugate CDMO Market Size by Application (2020-2025) & (\$ millions)

Table 26. Americas Antibody Drug Conjugate CDMO Market Size Market Share by Application (2020-2025)

Table 27. APAC Antibody Drug Conjugate CDMO Market Size by Region (2020-2025) & (\$ millions)

Table 28. APAC Antibody Drug Conjugate CDMO Market Size Market Share by Region (2020-2025)

Table 29. APAC Antibody Drug Conjugate CDMO Market Size by Type (2020-2025) & (\$ millions)

Table 30. APAC Antibody Drug Conjugate CDMO Market Size by Application (2020-2025) & (\$ millions)

Table 31. Europe Antibody Drug Conjugate CDMO Market Size by Country (2020-2025) & (\$ millions)

Table 32. Europe Antibody Drug Conjugate CDMO Market Size Market Share by Country (2020-2025)

Table 33. Europe Antibody Drug Conjugate CDMO Market Size by Type (2020-2025) & (\$ millions)

Table 34. Europe Antibody Drug Conjugate CDMO Market Size by Application (2020-2025) & (\$ millions)

Table 35. Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Region (2020-2025) & (\$ millions)

Table 36. Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Type (2020-2025) & (\$ millions)

Table 37. Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Application (2020-2025) & (\$ millions)

Table 38. Key Market Drivers & Growth Opportunities of Antibody Drug Conjugate CDMO

Table 39. Key Market Challenges & Risks of Antibody Drug Conjugate CDMO

Table 40. Key Industry Trends of Antibody Drug Conjugate CDMO

Table 41. Global Antibody Drug Conjugate CDMO Market Size Forecast by Region (2026-2031) & (\$ millions)

Table 42. Global Antibody Drug Conjugate CDMO Market Size Market Share Forecast by Region (2026-2031)

Table 43. Global Antibody Drug Conjugate CDMO Market Size Forecast by Type (2026-2031) & (\$ millions)

Table 44. Global Antibody Drug Conjugate CDMO Market Size Forecast by Application (2026-2031) & (\$ millions)

Table 45. Lonza Group Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors

Table 46. Lonza Group Antibody Drug Conjugate CDMO Product Offered

Table 47. Lonza Group Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 48. Lonza Group Main Business

Table 49. Lonza Group Latest Developments

Table 50. Porton Pharma Solutions Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors

Table 51. Porton Pharma Solutions Antibody Drug Conjugate CDMO Product Offered

Table 52. Porton Pharma Solutions Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 53. Porton Pharma Solutions Main Business

Table 54. Porton Pharma Solutions Latest Developments

Table 55. WuXi XDC Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors

Table 56. WuXi XDC Antibody Drug Conjugate CDMO Product Offered

Table 57. WuXi XDC Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 58. WuXi XDC Main Business

Table 59. WuXi XDC Latest Developments

Table 60. BOC Sciences Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors

Table 61. BOC Sciences Antibody Drug Conjugate CDMO Product Offered

Table 62. BOC Sciences Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 63. BOC Sciences Main Business

Table 64. BOC Sciences Latest Developments

Table 65. Asymchem Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors

Table 66. Asymchem Antibody Drug Conjugate CDMO Product Offered

Table 67. Asymchem Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 68. Asymchem Main Business

Table 69. Asymchem Latest Developments

Table 70. Catalent Biologics Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors

Table 71. Catalent Biologics Antibody Drug Conjugate CDMO Product Offered

Table 72. Catalent Biologics Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 73. Catalent Biologics Main Business

Table 74. Catalent Biologics Latest Developments

Table 75. 3PBIOVIAN Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors

Table 76. 3PBIOVIAN Antibody Drug Conjugate CDMO Product Offered

Table 77. 3PBIOVIAN Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 78. 3PBIOVIAN Main Business

Table 79. 3PBIOVIAN Latest Developments

Table 80. Genscript Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors

Table 81. Genscript Antibody Drug Conjugate CDMO Product Offered

Table 82. Genscript Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 83. Genscript Main Business

Table 84. Genscript Latest Developments

Table 85. AGC Biologics Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors

Table 86. AGC Biologics Antibody Drug Conjugate CDMO Product Offered

Table 87. AGC Biologics Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 88. AGC Biologics Main Business

Table 89. AGC Biologics Latest Developments

Table 90. MabPlex Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors

Table 91. MabPlex Antibody Drug Conjugate CDMO Product Offered

Table 92. MabPlex Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 93. MabPlex Main Business

Table 94. MabPlex Latest Developments

Table 95. ChemExpress Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors

Table 96. ChemExpress Antibody Drug Conjugate CDMO Product Offered

Table 97. ChemExpress Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 98. ChemExpress Main Business

Table 99. ChemExpress Latest Developments

Table 100. Abzena Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors

Table 101. Abzena Antibody Drug Conjugate CDMO Product Offered

Table 102. Abzena Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 103. Abzena Main Business

Table 104. Abzena Latest Developments

Table 105. Ajinomoto Bio-Pharma Services Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors

Table 106. Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Product Offered

Table 107. Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 108. Ajinomoto Bio-Pharma Services Main Business

Table 109. Ajinomoto Bio-Pharma Services Latest Developments

Table 110. BSP Pharmaceuticals Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors

Table 111. BSP Pharmaceuticals Antibody Drug Conjugate CDMO Product Offered

Table 112. BSP Pharmaceuticals Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 113. BSP Pharmaceuticals Main Business

Table 114. BSP Pharmaceuticals Latest Developments

Table 115. AbbVie Contract Manufacturing Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors

Table 116. AbbVie Contract Manufacturing Antibody Drug Conjugate CDMO Product Offered

Table 117. AbbVie Contract Manufacturing Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)

Table 118. AbbVie Contract Manufacturing Main Business

Table 119. AbbVie Contract Manufacturing Latest Developments

Table 120. TOT Biopharm Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors

Table 121. TOT Biopharm Antibody Drug Conjugate CDMO Product Offered
Table 122. TOT Biopharm Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)
Table 123. TOT Biopharm Main Business
Table 124. TOT Biopharm Latest Developments
Table 125. Huadong Medicine Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors
Table 126. Huadong Medicine Antibody Drug Conjugate CDMO Product Offered
Table 127. Huadong Medicine Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)
Table 128. Huadong Medicine Main Business
Table 129. Huadong Medicine Latest Developments
Table 130. Innovent Biologics Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors
Table 131. Innovent Biologics Antibody Drug Conjugate CDMO Product Offered
Table 132. Innovent Biologics Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)
Table 133. Innovent Biologics Main Business
Table 134. Innovent Biologics Latest Developments
Table 135. Zhenhao Biology Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors
Table 136. Zhenhao Biology Antibody Drug Conjugate CDMO Product Offered
Table 137. Zhenhao Biology Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)
Table 138. Zhenhao Biology Main Business
Table 139. Zhenhao Biology Latest Developments
Table 140. Porton Pharma Solutions Details, Company Type, Antibody Drug Conjugate CDMO Area Served and Its Competitors
Table 141. Porton Pharma Solutions Antibody Drug Conjugate CDMO Product Offered
Table 142. Porton Pharma Solutions Antibody Drug Conjugate CDMO Revenue (\$ million), Gross Margin and Market Share (2020-2025)
Table 143. Porton Pharma Solutions Main Business
Table 144. Porton Pharma Solutions Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Antibody Drug Conjugate CDMO Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Antibody Drug Conjugate CDMO Market Size Growth Rate (2020-2031) (\$ millions)

Figure 6. Antibody Drug Conjugate CDMO Sales by Geographic Region (2020, 2024 & 2031) & (\$ millions)

Figure 7. Antibody Drug Conjugate CDMO Sales Market Share by Country/Region (2024)

Figure 8. Antibody Drug Conjugate CDMO Sales Market Share by Country/Region (2020, 2024 & 2031)

Figure 9. Global Antibody Drug Conjugate CDMO Market Size Market Share by Type in 2024

Figure 10. Antibody Drug Conjugate CDMO in Small and Medium-sized Pharmaceutical Companies

Figure 11. Global Antibody Drug Conjugate CDMO Market: Small and Medium-sized Pharmaceutical Companies (2020-2025) & (\$ millions)

Figure 12. Antibody Drug Conjugate CDMO in Large Pharmaceutical Companies

Figure 13. Global Antibody Drug Conjugate CDMO Market: Large Pharmaceutical Companies (2020-2025) & (\$ millions)

Figure 14. Global Antibody Drug Conjugate CDMO Market Size Market Share by Application in 2024

Figure 15. Global Antibody Drug Conjugate CDMO Revenue Market Share by Player in 2024

Figure 16. Global Antibody Drug Conjugate CDMO Market Size Market Share by Region (2020-2025)

Figure 17. Americas Antibody Drug Conjugate CDMO Market Size 2020-2025 (\$ millions)

Figure 18. APAC Antibody Drug Conjugate CDMO Market Size 2020-2025 (\$ millions)

Figure 19. Europe Antibody Drug Conjugate CDMO Market Size 2020-2025 (\$ millions)

Figure 20. Middle East & Africa Antibody Drug Conjugate CDMO Market Size 2020-2025 (\$ millions)

Figure 21. Americas Antibody Drug Conjugate CDMO Value Market Share by Country in 2024

Figure 22. United States Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 23. Canada Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 24. Mexico Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 25. Brazil Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 26. APAC Antibody Drug Conjugate CDMO Market Size Market Share by Region in 2024

Figure 27. APAC Antibody Drug Conjugate CDMO Market Size Market Share by Type (2020-2025)

Figure 28. APAC Antibody Drug Conjugate CDMO Market Size Market Share by Application (2020-2025)

Figure 29. China Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 30. Japan Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 31. South Korea Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 32. Southeast Asia Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 33. India Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 34. Australia Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 35. Europe Antibody Drug Conjugate CDMO Market Size Market Share by Country in 2024

Figure 36. Europe Antibody Drug Conjugate CDMO Market Size Market Share by Type (2020-2025)

Figure 37. Europe Antibody Drug Conjugate CDMO Market Size Market Share by Application (2020-2025)

Figure 38. Germany Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 39. France Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 40. UK Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 41. Italy Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$

millions)

Figure 42. Russia Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 43. Middle East & Africa Antibody Drug Conjugate CDMO Market Size Market Share by Region (2020-2025)

Figure 44. Middle East & Africa Antibody Drug Conjugate CDMO Market Size Market Share by Type (2020-2025)

Figure 45. Middle East & Africa Antibody Drug Conjugate CDMO Market Size Market Share by Application (2020-2025)

Figure 46. Egypt Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 47. South Africa Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 48. Israel Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 49. Turkey Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 50. GCC Countries Antibody Drug Conjugate CDMO Market Size Growth 2020-2025 (\$ millions)

Figure 51. Americas Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 52. APAC Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 53. Europe Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 54. Middle East & Africa Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 55. United States Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 56. Canada Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 57. Mexico Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 58. Brazil Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 59. China Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 60. Japan Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 61. Korea Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 62. Southeast Asia Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 63. India Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 64. Australia Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 65. Germany Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$

millions)

Figure 66. France Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 67. UK Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 68. Italy Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 69. Russia Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 70. Egypt Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 71. South Africa Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 72. Israel Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 73. Turkey Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

Figure 74. Global Antibody Drug Conjugate CDMO Market Size Market Share Forecast by Type (2026-2031)

Figure 75. Global Antibody Drug Conjugate CDMO Market Size Market Share Forecast by Application (2026-2031)

Figure 76. GCC Countries Antibody Drug Conjugate CDMO Market Size 2026-2031 (\$ millions)

I would like to order

Product name: Global Antibody Drug Conjugate CDMO Market Growth (Status and Outlook) 2025-2031

Product link: <https://marketpublishers.com/r/G1D1C64FF12DEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1D1C64FF12DEN.html>